A massive parallel sequencing workflow for diagnostic genetic testing of mismatch repair genes

Molecular Genetics and Genomic Medicine

Volumn 2, Issue 2, 2014, Pages 186-200

  Hansen, Maren F ^a   Neckmann, Ulrike ^a   Lavik, Liss A S ^b   Vold, Trine ^b   Gilde, Bodil ^b   Toft, Ragnhild K ^a   Sjursen, Wenche ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Amplicon sequencing; Diagnostics; Hereditary colorectal cancer; Massive parallel sequencing; Mismatch repair; MLH1; MSH2; MSH6; PMS2

Indexed keywords

EID: 84939552146     PISSN: None     EISSN: 23249269     Source Type: Journal    
DOI: 10.1002/mgg3.62     Document Type: Article

References (34)

1. Albert, T. J., M. N. Molla, D. M. Muzny, L. Nazareth, D. Wheeler, X. Song, et al. 2007. Direct selection of human genomic loci by microarray hybridization. Nat. Methods 4:903–905.
2. ten Bosch, J. R., and W. W. Grody. 2008. Keeping up with the next generation: massively parallel sequencing in clinical diagnostics. J. Mol. Diagn. 10:484–492.
3. Bozzao, C., P. Lastella, and A. Stella. 2011. Anticipation in Lynch syndrome: where we are where we go. Curr. Genomics 12:451–465.
4. Chou, L. S., C. S. Liu, B. Boese, X. Zhang, and R. Mao. 2010. DNA sequence capture and enrichment by microarray followed by next-generation sequencing for targeted resequencing: neurofibromatosis type 1 gene as a model. Clin. Chem. 56:62–72.
5. De Leeneer, K., J. De Schrijver, L. Clement, M. Baetens, S. Lefever, S. De Keulenaer, et al. 2011a. Practical tools to implement massive parallel pyrosequencing of PCR products in next generation molecular diagnostics. PLoS One 6:e25531.
6. De Leeneer, K., J. Hellemans, J. De Schrijver, M. Baetens, B. Poppe, W. Van Criekinge, et al. 2011b. Massive parallel amplicon sequencing of the breast cancer genes BRCA1 and BRCA2: opportunities, challenges, and limitations. Hum. Mutat. 32:335–344.
7. De Vos, M., B. E. Hayward, S. Picton, E. Sheridan, and D. T. Bonthron. 2004. Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am. J. Hum. Genet. 74:954–964.
8. Etzler, J., A. Peyrl, A. Zatkova, H. U. Schildhaus, A. Ficek, S. Merkelbach-Bruse, et al. 2008. RNA-based mutation analysis identifies an unusual MSH6 splicing defect and circumvents PMS2 pseudogene interference. Hum. Mutat. 29:299–305.
9. Feliubadalo, L., A. Lopez-Doriga, E. Castellsague, J. Del Valle, M. Menendez, E. Tornero, et al. 2012. Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes. Eur. J. Hum. Genet. 21:864–870.
10. Gnirke,A.,A.Melnikov,J.Maguire,P.Rogov,E.M. LeProust, W. Brockman, et al. 2009. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat. Biotechnol. 27:182–189.
11. Hampel, H., W. L. Frankel, E. Martin, M. Arnold, K. Khanduja, P. Kuebler, et al. 2008. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J. Clin. Oncol. 26:5783–5788.
12. Hayward, B. E., M. De Vos, E. M. Valleley, R. S. Charlton, G. R. Taylor, E. Sheridan, et al. 2007. Extensive gene conversion at the PMS2 DNA mismatch repair locus. Hum. Mutat. 28:424–430.
13. Hernan, I., E. Borras, D. M. de Sousa, M. J. Gamundi, B. Mane, G. Llort, et al. 2012. Detection of genomic variations in BRCA1 and BRCA2 genes by long-range PCR and next-generation sequencing. J. Mol. Diagn. 14:286–293.
14. Huse, S. M., J. A. Huber, H. G. Morrison, M. L. Sogin, and D. M. Welch. 2007. Accuracy and quality of massively parallel DNA pyrosequencing. Genome Biol. 8:R143.
15. Jiang, Q., T. Turner, M. X. Sosa, A. Rakha, S. Arnold, and A. Chakravarti. 2012. Rapid and efficient human mutation detection using a bench-top next-generation DNA sequencer. Hum. Mutat. 33:281–289.
16. Liu, L., Y. Li, S. Li, N. Hu, Y. He, R. Pong, et al. 2012. Comparison of next-generation sequencing systems. J. Biomed. Biotechnol. 2012:251364.
17. Margulies, M., M. Egholm, W. E. Altman, S. Attiya, J. S. Bader, L. A. Bemben, et al. 2005. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437:376–380.
18. Mattocks, C. J., M. A. Morris, G. Matthijs, E. Swinnen, A. Corveleyn, E. Dequeker, et al. 2010. A standardized framework for the validation and verification of clinical molecular genetic tests. Eur. J. Hum. Genet. 18:1276–1288.
19. Michils, G., S. Hollants, L. Dehaspe, J. Van Houdt, Y. Bidet, N. Uhrhammer, et al. 2012. Molecular analysis of the breast cancer genes BRCA1 and BRCA2 using amplicon-based massive parallel pyrosequencing. J. Mol. Diagn. 14:623–630.
20. Morgan, J. E., I. M. Carr, E. Sheridan, C. E. Chu, B. Hayward, N. Camm, et al. 2010. Genetic diagnosis of familial breast cancer using clonal sequencing. Hum. Mutat. 31:484–491.
21. Nakagawa, H., J. C. Lockman, W. L. Frankel, H. Hampel, K. Steenblock, L. J. Burgart, et al. 2004. Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation. Cancer Res. 64:4721–4727.
22. Nicolaides, N. C., K. C. Carter, B. K. Shell, N. Papadopoulos, B. Vogelstein, and K. W. Kinzler. 1995. Genomic organization of the human PMS2 gene family. Genomics 30:195–206.
23. Peltomaki, P. 2005. Lynch syndrome genes. Fam. Cancer 4:227–232.
24. Plon, S. E., D. M. Eccles, D. Easton, W. D. Foulkes, M. Genuardi, M. S. Greenblatt, et al. 2008. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum. Mutat. 29:1282–1291.
25. Rothberg, J. M., and J. H. Leamon. 2008. The development and impact of 454 sequencing. Nat. Biotechnol. 26:1117–1124.
26. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463–5467.
27. Sjursen, W., B. I. Haukanes, E. M. Grindedal, H. Aarset, A. Stormorken, L. F. Engebretsen, et al. 2010. Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers. J. Med. Genet. 47:579–585.
28. Spurdle, A. B. 2010. Clinical relevance of rare germline sequence variants in cancer genes: evolution and application of classification models. Curr. Opin. Genet. Dev. 20:315–323.
29. Tompa, M., N. Li, T. L. Bailey, G. M. Church, B. De Moor, E. Eskin, et al. 2005. Assessing computational tools for the discovery of transcription factor binding sites. Nat. Biotechnol. 23:137–144.
30. Trano, G., W. Sjursen, H. H. Wasmuth, E. Hofsli, and L. J. Vatten. 2010. Performance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: a Norwegian population-based study. Br. J. Cancer 102:482–488.
31. Vaughn, C. P., J. Robles, J. J. Swensen, C. E. Miller, E. Lyon, R. Mao, et al. 2010. Clinical analysis of PMS2: mutation detection and avoidance of pseudogenes. Hum. Mutat. 31:588–593.
32. Walsh, T., M. K. Lee, S. Casadei, A. M. Thornton, S. M. Stray, C. Pennil, et al. 2010. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc. Natl. Acad. Sci. USA 107:12629–12633.
33. Zheng, Z., A. Advani, O. Melefors, S. Glavas, H. Nordstrom, W. Ye, et al. 2010. Titration-free massively parallel pyrosequencing using trace amounts of starting material. Nucleic Acids Res. 38:e137.
34. Zvelebil, M., and J. O. Baum. 2007. P. 356 in Understanding bioinformatics. Garland Science, New York.